Ocugen’s Lead in Eye Therapy Race Threatened by Rival’s Progress
03.12.2025 - 12:44:05Ocugen US67577C1053
Investors in Ocugen, a biotechnology firm focused on genetic treatments for rare eye diseases, were met with unsettling news in early December 2025. A direct competitor has surged ahead in the development of a therapy for Stargardt disease, casting doubt on the commercial future of Ocugen’s parallel program and sending its shares lower.
The catalyst was an announcement from Belite Bio on December 1, 2025. The company revealed that its Phase 3 clinical trial, named DRAGON, for a Stargardt disease treatment had successfully met its primary endpoint. The drug candidate, Tinlarebant, was shown to reduce lesion growth by 36 percent. With these positive results in hand, Belite Bio is preparing to seek Read more...
